Atsena gene therapy shows promise in blindness trial
Atsena's ATSN-201 gene therapy showed sustained benefit in a trial for X-linked retinoschisis, an inherited cause of blindness, per company-reported data.
Simple explainers on world affairs, science, health and more.
All news under one minute
Atsena's ATSN-201 gene therapy showed sustained benefit in a trial for X-linked retinoschisis, an inherited cause of blindness, per company-reported data.
University of Manchester researchers have built a graphene-based sensor they say gives doctors a real-time window into stroke damage in the brain.
Kodiak Sciences will present Phase 3 DAYBREAK data for Zenkuda and tabirafusp-ted in wet AMD at AAO 2026 after the trial met…
Firmus Technologies withdrew its A$44 billion ASX IPO after investors balked at the valuation; the Nvidia-backed data centre firm will seek private…
Nana Patekar once revealed Horn 'OK' Pleassss struggled to release because distributors offered Rs 18 crore but producers wanted more.
The latest Drishyam film is nearing Rs 400 crore at the box office after a Rs 375-383 crore first week, according to…
Chelsea boss Enzo Maresca held his first press conference since Man City's guilty verdict, ahead of Sunday's trip to the Etihad.
Gravita India has incorporated a recycling subsidiary in Maputo, Mozambique, expanding its lead, aluminium and plastics recycling footprint in Africa.
French students continue high-school blockades over teacher shortages and decaying buildings as PM Lecornu promises action and unions plan an October 17…
New Zealand's censor says it cannot classify or block a livestreamed US execution, as the Pentagon plans to broadcast Nidal Hasan's firing…